Skip to main content
. Author manuscript; available in PMC: 2018 Jan 1.
Published in final edited form as: Biol Blood Marrow Transplant. 2016 Oct 24;23(1):60–66. doi: 10.1016/j.bbmt.2016.10.010

Table 2.

Patient outcomes based on conditioning intensity

Myeloablative (N=67) Reduced intensity (N=67)
Outcomes N Eval Prob (95% CI) N Eval Prob (95% CI)
NRM 61 56
    1-year 12 (6-24)% 15 (9-27)%
    3-year 21 (12-33)% 33 (21-48)%
    5-year 24 (12-36)% 39 (24-51)%
Relapse/Prog 61 56
    1-year 18 (9-30)% 15 (9-27)%
    3-year 24 (15-36)% 21 (12-33)%
    5-year 27 (15-39)% 21 (12-33)%
PFS 61 56
    1-year 69 (56-80)% 68 (55-79)%
    3-year 55 (42-68)% 46 (32-60)%
    5-year 50 (36-63)% 41 (27-55)%
OS 67 67
    1-year 73 (62-83)% 73 (62-83)%
    3-year 60 (47-71)% 50 (37-62)%
    5-year 55 (43-68)% 45 (33-58)%

Overall survival (OS); progression (Prog); progression free survival (PFS); non-relapse mortality (NRM)